Please login to the form below

Not currently logged in
Email:
Password:

irritable bowel syndrome

This page shows the latest irritable bowel syndrome news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt pays $1.2bn for Sucampo Pharma

Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic constipation as well as constipation linked to irritable bowel syndrome and chronic opioid

Latest news

More from news
Approximately 1 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... This campaign showed doctors suffering from Irritable Disbelief Syndrome (IDS) - a brave move but exactly the perception shift

  • Taking a lean and careful approach Taking a lean and careful approach

    His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation. ... ulcerative colitis, type 1 diabetes and inflammatory bowel disease.

  • Can biosimilars live up to the hype? Can biosimilars live up to the hype?

    She is convinced that biosimilars are essential in treating patients with chronic conditions such as rheumatoid arthritis, irritable bowel syndrome and psoriasis, because they provide the same uplift in quality of

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... Among these are Avaxia Biologics, which

  • Pharma deals during April 2014 Pharma deals during April 2014

    associated with nephrotic syndrome, certain rheumatology-related conditions, and infantile spasms. ... Eluxadoline is a first-in-class, locally-acting mu opioid receptor agonist/ delta opioid receptor antagonist for treating symptoms of

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics